Triplet Therapy, Transplantation, and Maintenance until Progression in MyelomaPaul G. Richardson, Irene M. Ghobrial, Krisstina Gowin et al.|New England Journal of Medicine|2022Cited by 457
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I StudySuzanne Trudel, Simon J. Harrison, Adam D. Cohen et al.|Blood|2021Cited by 161
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström MacroglobulinemiaSteven P. Treon, Jorge J. Castillo, Kirsten Meid et al.|Journal of Clinical Oncology|2020Cited by 150
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myelomaTorben Plesner, Paul G. Richardson, Hendrik‐Tobias Arkenau et al.|Blood|2016Cited by 110
Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple MyelomaTorben Plesner, Paul G. Richardson, Hendrik‐Tobias Arkenau et al.|Blood|2014Cited by 49